secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0000950170-22-014751
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX Q2 2022 revenue $18M; cash $228M; restructuring extends runway to 2025
-----------------------------------------------------------------------------

- Cash and investments $228M at June 30, 2022, down from $305M at Dec 31, 2021.
- Total revenue $18M for Q2 2022, up from $16M in Q2 2021; R&D expense $31M (+$5M YoY).
- Company restructuring announced July 2022 aims to extend cash runway into 2025.
- IND filings planned for CX-801 (IFN alpha-2b) and CX-2051 (EpCAM ADC) in H2 2023.
- CX-2029 data update for squamous NSCLC expected Q4 2022; praluzatamab ravtansine also updating Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000095017022014751/0000950170-22-014751-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000095017022014751/ctmx-20220804.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-014751

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer